- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07766642
A Clinical Trial to Evaluate the Effects of a Supplement on Children's Focus and Energy
This study will evaluate the effects of the Auri Super Mushroom Daily Gummies For Kids on focus and energy in children aged 4-12. The study is a single-arm, unblinded, virtual trial conducted over 8 weeks, in which all 35 enrolled participants will use the test product daily.
Parents of the participants will complete questionnaires at Baseline, Week 2, Week 4, Week 6, and Week 8 to assess perceived changes in their child's focus, attention, sleep quality, gut health, natural energy, and overall well-being. Participants will also undergo cognitive battery testing at Baseline, Week 4, and Week 8 to provide objective measurements of focus and cognitive performance.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89101
- Citruslabs
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
Accepte les volontaires sains
La description
Inclusion Criteria:
- Be male or female.
- Be aged 4-12.
- Parent(s) reporting that their child has been experiencing issues regarding any of the following for the past four weeks: Difficulty focusing, Poor concentration, or Poor memory.
- Parent(s) who report that their child will be willing to complete cognitive assessments at regular intervals during the study.
- Any child who is generally healthy - does not live with any uncontrolled chronic disease.
- Parent(s) who are willing to follow the study protocol and support their child to complete all study actions.
- Any child who has no planned changes to school schedule, sleep routines, or behavioral therapies during the study duration.
- Anyone willing to refrain from introducing any new prescription medications, wellness products, supplements, or herbal remedies into their child's routine during the test period.
- If the child has been taking any other products, supplements, or herbal remedies, they have been taking these consistently for at least three months.
- Has had a stable diet and sleep schedule for at least four weeks prior to the study.
- Enrolled in and currently attending school at baseline and for the duration of the study period.
- Resides in the United States.
Exclusion Criteria:
- Any child with a neurodevelopmental condition or developmental delay, including autism spectrum disorder, intellectual disability, language disorder, uncontrolled anxiety or mood disorder, or dyslexia.
- Previous diagnosis of Attention-deficit hyperactivity disorder (ADHD).
- Any child currently undergoing any assessments for suspected neurodevelopmental conditions or developmental delay.
- Any child diagnosed with epilepsy or a seizure disorder.
- Any child diagnosed with a bleeding disorder.
- Any child with any known allergies or hypersensitivities to any supplement product ingredients.
- Any child with any chronic health conditions that could impact their participation in this study, such as cancer, mental health disorders, a history of serious illness in the last three months, or planned surgery during the study period.
- Any parent or child currently testing, or planning on starting in the next eight weeks, a product for another research study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Auri Super Mushroom Daily Gummies For Kids
|
All participants receive two Auri Super Mushroom Daily Gummies once daily in the morning with their first meal of the day for 8 weeks.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Focus
Délai: Baseline, Week 4, and Week 8
|
Assessed via cognitive battery testing (Polygons, Double Trouble, Feature Match, Paired Associates, Digit Span, Spatial Planning) and self-reported questionnaire
|
Baseline, Week 4, and Week 8
|
|
Change in Cognitive Performance
Délai: Baseline, Week 4, and Week 8
|
Assessed via cognitive battery testing (Polygons, Double Trouble, Feature Match, Paired Associates, Digit Span, Spatial Planning) and self-reported questionnaire
|
Baseline, Week 4, and Week 8
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Parent-Reported Focus
Délai: Baseline, Week 2, Week 4, Week 6, and Week 8
|
Assessed via parent-completed self-reported questionnaire
|
Baseline, Week 2, Week 4, Week 6, and Week 8
|
|
Change in Parent-Reported Attention
Délai: Baseline, Week 2, Week 4, Week 6, and Week 8
|
Assessed via parent-completed self-reported questionnaire
|
Baseline, Week 2, Week 4, Week 6, and Week 8
|
|
Change in Parent-Reported Sleep Quality
Délai: Baseline, Week 2, Week 4, Week 6, and Week 8
|
Assessed via parent-completed self-reported questionnaire
|
Baseline, Week 2, Week 4, Week 6, and Week 8
|
|
Change in Parent-Reported Gut Health
Délai: Baseline, Week 2, Week 4, Week 6, and Week 8
|
Assessed via parent-completed self-reported questionnaire
|
Baseline, Week 2, Week 4, Week 6, and Week 8
|
|
Change in Parent-Reported Natural Energy
Délai: Baseline, Week 2, Week 4, Week 6, and Week 8
|
Assessed via parent-completed self-reported questionnaire
|
Baseline, Week 2, Week 4, Week 6, and Week 8
|
|
Change in Parent-Reported Overall Well-Being
Délai: Baseline, Week 2, Week 4, Week 6, and Week 8
|
Assessed via parent-completed self-reported questionnaire
|
Baseline, Week 2, Week 4, Week 6, and Week 8
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 20827
- legacy-20827
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .